{
    "clinical_study": {
        "@rank": "36745", 
        "arm_group": [
            {
                "arm_group_label": "Vehicle gel", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "SR-T100 gel with 1.0 % SM", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "SR-T100 gel with 2.3% SM", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy of SR-T100 gel by observing total clearance rate of treated\n      baseline EGW(s) on the treated area."
        }, 
        "brief_title": "Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Condyloma Acuminata", 
            "Genital Warts", 
            "Condylomata Acuminata", 
            "Venereal Warts"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Condylomata Acuminata", 
                "Warts"
            ]
        }, 
        "detailed_description": {
            "textblock": "A double-blind, randomized,vehicle-controlled, parallel-group, and dose-ranging study  to\n      evaluate the efficacy and safety of SR-T100 gel in patients with EGW(s). The primary\n      efficacy endpoint will be defined as the proportion of patients whose baseline EGW(s) on the\n      treated area achieve total clearance. The efficacy of SR-T100 gel in prevention of new\n      EGW(s) occurrence will be evaluated. Distinct to existing medications for EGWs, SR-T100 gel\n      possesses characteristics of high safety and low LSR causality. SR-T100 gel will be\n      administered on EGW lesion(s) for clearance and on the surrounding clinical normal skin for\n      prevention of new EGW(s) occurrence."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female; aged \u2265 20 years old.\n\n          2. Patients who accept to enter the study by signing written informed consent.\n\n          3. Each patient has 1 to 10 clinically diagnosed EGW(s). If patient has only 1 genital\n             wart, the diameter of the genital wart must be no less than 5 mm.\n\n          4. Female patients have  lesion(s) on labia majora, labia minora, clitoris and/or groin.\n\n          5. Male patients have lesion(s) on glans, shaft and/or foreskin.\n\n          6. Each patient has at least 1 histologically proved EGW.\n\n          7. Patients agree to apply the study medication on  \"clinical diagnosed lesion(s)\" with\n             occlusive dressing(s) once daily for at least 20 hours per day and  \"clinical normal\n             skin  on the treated area\" thrice daily without occlusive dressing.\n\n          8. Patients allow diagrammed mapping and photography on genital warts. And patients\n             agree to be used of these data as part of the study data package.\n\n          9. Patients in good general health condition (performance status \u2264 2 Eastern Cooperative\n             Oncology Group (ECOG)).\n\n         10. Female patients with child-bearing potential must take reliable contraception\n             method(s) during the participation of the study.\n\n         11. Patients must agree to use effective boundary barrier for birth control and\n             re-infection of EGW\n\n        Exclusion Criteria:\n\n          1. Patients with peri-anal warts.\n\n          2. Male patients with warts on scrotum or perineum.\n\n          3. Patients with other genital infections.\n\n          4. Patients with internal genital warts (such as urethral, intra-vaginal, cervical,\n             rectal, or intra-anal genital warts).\n\n          5. Patients with active systemic infections.\n\n          6. Patients with other genital diseases that may confound evaluation and treatment for\n             genital warts.\n\n          7. Patients with immuno-compromised medical condition.\n\n          8. Patients have received investigational drug prior to 30 days of randomization visit.\n\n          9. Patients with cancer or cancer history within 5 years of the randomization visit.\n\n         10. Patients have on-going human papilloma virus (HPV) infection other than genital area.\n\n         11. Patients with human immunodeficiency virus (HIV), venereal disease research\n             laboratory (VDRL), or treponema pallidum particle agglutination assay (TPHA) positive\n             result.\n\n         12. Female patients have high-grade pathology in Papanicolaou smear tests based on\n             Bethesda system.\n\n         13. Female patients are pregnant or lactating.\n\n         14. Patients have history of allergy or sensitivity to Solanum undatum plant extract, SM,\n             or SR-T100 gel excipients including carbomer, propylene glycol, and triethanolamine.\n\n         15. Patients with prohibited pre-medication or procedures shown below:\n\n               1. Physical modalities, such as laser ablation, electrocautery or cryotherapy, for\n                  genital warts treatment on treated area within 4 weeks prior to randomization\n                  visit.\n\n               2. Topical administered medication for genital warts treatment, such as polyphenon\n                  E, podophyllotoxin, imiquimod, or 5-fluorouracil (5-FU), within 12 weeks prior\n                  to randomization.\n\n               3. Medications of cytotoxic, immunomodulator (inhaled and topical steroid not on\n                  ano-genital areas are not prohibited), systematic antiviral agent in 4 weeks\n                  prior to randomization visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796821", 
            "org_study_id": "GESRTGWA"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vehicle gel", 
                "description": "Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.\nClinical normal skin on treated area: Topical application thrice daily without occlusive dressing.\nTotal application <1,500 mg gel per day.", 
                "intervention_name": "Vehicle gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SR-T100 gel with 1.0 % SM", 
                "description": "Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.\nClinical normal skin on treated area: Topical application thrice daily without occlusive dressing.\nTotal application <1,500 mg gel per day.", 
                "intervention_name": "SR-T100 gel with 1.0 % SM", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SR-T100 gel with 2.3% SM", 
                "description": "Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.\nClinical normal skin on treated area: Topical application thrice daily without occlusive dressing.\nTotal application <1,500 mg gel per day.", 
                "intervention_name": "SR-T100 gel with 2.3% SM", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Condyloma acuminata", 
            "Genital warts", 
            "Condylomata acuminata", 
            "Venereal warts"
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": [
            {
                "contact": {
                    "email": "cnhuang.uro@gmail.com", 
                    "last_name": "Chun-Nung Huang, MD. Ph.D.", 
                    "phone": "886-7-3121101", 
                    "phone_ext": "6694"
                }, 
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan"
                    }, 
                    "name": "Kaohsiung Medical University Chung-Ho Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "Chun-Nung Huang, MD. PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "d5580@mail.ncku.edu.tw", 
                    "last_name": "Keng-Fu Hsu, MD. Ph.D.", 
                    "phone": "886-6-2353535", 
                    "phone_ext": "5263"
                }, 
                "facility": {
                    "address": {
                        "city": "Tainan", 
                        "country": "Taiwan"
                    }, 
                    "name": "National Cheng Kung University Hospital"
                }, 
                "investigator": {
                    "last_name": "Keng-Fu Hsu, MD. PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts/Condyloma Acuminate (EGWs)", 
        "overall_contact": {
            "email": "kwkuo@geherbs.com.tw", 
            "last_name": "Kou-Wha Kuo, Ph.D.", 
            "phone": "+886-6-505-2976", 
            "phone_ext": "201"
        }, 
        "overall_contact_backup": {
            "email": "hsiaowen.su@geherbs.com.tw", 
            "last_name": "Hsiao-Wen Su, Ph.D.", 
            "phone": "+886-6-505-2976", 
            "phone_ext": "226"
        }, 
        "overall_official": [
            {
                "affiliation": "G&E Herbal Biotechnology Co., LTD", 
                "last_name": "Kou-Wha Kuo, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "National Cheng Kung University, Tainan, Taiwan", 
                "last_name": "Cheng-Yang Chou, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Taiwan : Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Total clearance rate of baseline lesion(s)", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796821"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total clearance rate of all lesion(s)", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Period duration of achieving total clearance of baseline  lesion(s) and new lesion(s)", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Partial clearance rate", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "New lesion(s) occurrence rate", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "measure": "Recurrence rate in the 12-week follow-up time", 
                "safety_issue": "No", 
                "time_frame": "28 weeks"
            }, 
            {
                "measure": "Recurrence time period", 
                "safety_issue": "No", 
                "time_frame": "28 weeks"
            }, 
            {
                "description": "including PE, vital sign, lab. test, local skin reaction, and adverse event, etc.", 
                "measure": "Safety: evaluate the changes occurring from baseline to EOT visit", 
                "safety_issue": "Yes", 
                "time_frame": "28 weeks"
            }
        ], 
        "source": "G&E Herbal Biotechnology Co., LTD", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "G&E Herbal Biotechnology Co., LTD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}